Trial · NCT07037836
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
NCT07037836, Phase 2, Recruiting, Bastiaan Driehuys
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia. Trials, record NCT07037836. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07037836
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
- NCT number
- NCT07037836
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Bastiaan Driehuys
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
- Interventions
- Inhaled Treprostinil (Tyvaso Nebulizer)
- First posted
- 2025-06-26
- Last updated
- 2026-08-27
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ventilation Defect Percentage (VDP) on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with ventilation signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Membrane Defect Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with membrane signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Low Membrane Region Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with membrane signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | RBC Transfer Defect Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with RBC transfer signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Low RBC Transfer Region Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with RBC transfer signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | RBC Oscillation Amplitude Normalized for RBC Transfer Defect | Baseline and 4 weeks post-Tyvaso | Measured using HP129XeMRI spectroscopy as a surrogate for pulmonary vascular resistance, normalized to RBC transfer signal intensity. |
| Primary | RBC Chemical Shift on HP129XeMRI Spectroscopy | Baseline and 4 weeks post-Tyvaso | Frequency shift in RBC signal reflecting capillary blood oxygenation, measured using HP129XeMRI spectroscopy. |
| Secondary | Nadir SpO₂ During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Lowest oxygen saturation (SpO₂) recorded during the 6-minute walk test, measured by pulse oximetry. The test is performed on room air unless SpO₂ drops below 89%, at which point supplemental oxygen is administered to maintain SpO₂ ≥89%. |
| Secondary | Supplemental Oxygen Flow During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Oxygen flow rate in liters per minute required to maintain SpO₂ ≥89% during the 6-minute walk test if room air is insufficient. |
| Secondary | 6-Minute Walk Distance (6MWD) | Baseline and 4 weeks post-Tyvaso treatment | Total distance walked in meters during the 6-minute walk test, following ATS guidelines. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07037836
GET https://conductscience.org/api/trials/v1/NCT07037836/registered